OCT
- Company typePrivate
- Founded2005
- HeadquartersHamburg, Germany
- Headcount101–250
- GTM typeB2B
- OfferingServices
OCT firmographics
Firmographics- Name
- OCT
- Legal name
- OCT Group LLC
- Website
- https://oct-clinicaltrials.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
OCT industry classification
Industry- Product category
- Contract Research Organization Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where OCT is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices11 records
Markets served
OCT business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Full-Service Clinical Trial Management: Comprehensive Phase I-IV and BE clinical trial services including project management, monitoring, data management, biostatistics, regulatory support, and drug safety. Charges on a per-study, per-service basis.
- Standalone/Partial Services: Individual clinical development services offered separately including specific therapeutic area expertise, site management, feasibility studies, and specialized consulting.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
OCT product offering
Product offeringCore offering
OCT is a full-service Contract Research Organization (CRO) that conducts Phase I–IV clinical trials and bioequivalence studies, primarily across Eastern Europe and CIS countries. The company delivers end-to-end clinical research services including study design, regulatory and marketing-authorization support, project management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, and clinical supply logistics. OCT also offers dedicated oncology solutions (OCT Oncology™), rescue studies for stalled trials, and a free feasibility report as a pre-engagement offering.
Product overview
OCT is a full-service Clinical Research Organization (CRO) providing comprehensive clinical trial services for Phase I-IV and BE (bioequivalence) studies. The company offers both full-service clinical study engagements and standalone services across 21 countries with access to 2,100 leading research sites. The core service portfolio includes Clinical Study Design Preparation, MedSci Consulting and Excellence™, Consulting and Regulatory Support, Drug Safety and Pharmacovigilance, Project Management and Monitoring, Clinical Data Management, Biostatistics, Clinical Supply Services and Logistics, Medical Writing, and Marketing Authorization Support. The company also offers specialized service packages including OCT Oncology™ for dedicated oncology solutions and Rescue Studies for troubled clinical trials. Since 2005, OCT has conducted over 300 studies across 29 therapeutic areas including Oncology, Gastroenterology, Rheumatology, Neurology, Infectious Diseases, and Respiratory Diseases.
Differentiator
Problem solved
Functional benefit
Brands
- OCT Oncology™: A dedicated solutions package aimed at helping pharma from early to late stage oncology treatment development. Includes access to 300 leading oncology clinics in 10 countries and specialized immuno-oncology study expertise.
Products and services
- Phase I–IV Clinical Trial Management End-to-end management of Phase I, II, III, and IV clinical trials, including site activation, patient enrollment, monitoring, and closeout, primarily across Eastern Europe and CIS countries.
- Bioequivalence Studies Bioequivalence study services to support generic and biosimilar development programs for pharmaceutical sponsors.
- Rescue Studies Specialized services to take over, re-energize, and complete stalled or under-enrolling clinical trials transferred from other CROs or sponsors.
- OCT Oncology™ Dedicated oncology clinical trial services with specialized protocol design, oncology-experienced sites, and an oncology-focused operations unit, covering 80+ oncology studies and 35,466 oncology patients.
- MedSci Consulting and Excellence™ Scientific and medical consulting services to support clinical development strategy, protocol design, and study planning for pharmaceutical and biotech sponsors.
- Regulatory and Marketing Authorization Support Regulatory affairs consulting and marketing authorization application support for EMA, FDA, and regional Eastern European/CIS submissions.
- Drug Safety and Pharmacovigilance
- Biostatistics and Data Management
- Medical Writing
- Clinical Supply Services and Logistics
- Free Feasibility Report
Quantifiable outcome
- Up to 4x faster enrollment rates compared to other regions
- +3 more outcomes
Companies that use OCT
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
OCT technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
OCT partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EUCROF (European CRO Federation)moderateOCT is an official member of the European CRO Federation, an industry organization representing clinical research organizations across Europe. This membership provides access to industry best practices, regulatory updates, and networking within the European clinical research community.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
OCT competitors and assessment
Company assessmentBroad incumbents
- Medpace Holdings: Mid-to-large CRO with strong oncology franchise and full-service Phase I-IV delivery. Comparable therapeutic mix though larger and US-centric.
- Parexel International: Large global CRO with full Phase I-IV services and significant biopharma client base. Competes for enterprise study awards where OCT also bids.
- ICON plc: Top-3 global CRO offering full-service clinical development across all phases and geographies. Represents the most direct large-scale competitor for Eastern European Phase II/III awards.
- IQVIA: Largest global CRO with extensive technology stack and broad sponsor relationships. Sets the competitive ceiling for mid-size CROs competing for global Phase III work.
- Syneos Health: Global biopharma solutions organization combining CRO and commercial services. Competes for full-service clinical work across multiple therapeutic areas.
Direct peers
- Worldwide Clinical Trials: Mid-size global CRO offering Phase I-IV services with therapeutic area depth including oncology and CNS. Similar size tier and full-service positioning.
- PSI CRO: Switzerland-based mid-size CRO with deep Central and Eastern European site network and full-service Phase I-IV capabilities. Highly comparable operating model and regional positioning.
- Ergomed plc: UK-headquartered mid-size CRO with strong Central and Eastern European footprint and oncology specialization. Closely comparable in size, geographic focus, and service mix.
Emerging players
- Clinipace Worldwide: Smaller mid-size CRO offering full-service clinical development with therapeutic focus areas. Comparable size tier and service model to OCT.
- Catalyst Clinical Research: Mid-size oncology-focused CRO with similar therapeutic concentration. Comparable as an oncology-specialized competitor for biotech Phase II/III work.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OCT social profiles
Digital presenceOCT compliance and trust
Trust signalCompliance2 records
OCT financial estimates
Financial estimateRevenue estimate
Valuation estimate
OCT leadership team
Management profileNumber of profiles
Profiles4 records
OCT funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OCT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OCT
What does OCT do?
OCT is a full-service Contract Research Organization (CRO) that conducts Phase I–IV clinical trials and bioequivalence studies, primarily across Eastern Europe and CIS countries. The company delivers end-to-end clinical research services including study design, regulatory and marketing-authorization support, project management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, and clinical supply logistics. OCT also offers dedicated oncology solutions (OCT Oncology™), rescue studies for stalled trials, and a free feasibility report as a pre-engagement offering.
Is OCT a public or private company?
OCT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OCT founded?
OCT was founded in 2005. It employs 101 to 250 people.
Where is OCT based?
OCT is headquartered in Hamburg, Germany, in the Europe region.
How does OCT make money?
Two revenue lines are on record. Full-Service Clinical Trial Management is the primary driver. The others are standalone/Partial Services.
Who are OCT's main competitors?
Broad incumbents on record are Medpace Holdings, Parexel International, ICON plc, IQVIA and Syneos Health. Direct peers are Worldwide Clinical Trials, PSI CRO and Ergomed plc. Emerging players are Clinipace Worldwide and Catalyst Clinical Research.
Does OCT have an API?
No public API is recorded for OCT.
What industry is OCT in?
OCT's product category is Contract Research Organization Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.